Literature DB >> 15027114

Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.

Hui Huang1, Jim Xiang.   

Abstract

The lack of efficient T-cell infiltration of tumors is a major obstacle to successful adoptive T-cell therapy. We have previously demonstrated that adenovirus (AdV)-mediated transgene lymphotactin (Lptn) or IP-10 expression in tumors can significantly enhance T-cell tumor infiltration. In this study, active OVA-specific CD8+ T cells were prepared by coculturing naive OVA-specific CD8+ T cells from transgenic OT I mice with OVA-I peptide-pulsed dendritic cells in vitro. These XCR-1- and CXCR3-expressing T cells predominantly secreted IFN-gamma and displayed significant killing activity (84% at effector:target cell ratio of 1.5) against OVA-expressing EG7 tumor cells through perforin-mediated pathway. Our data also showed that chemokine Lptn and IP-10 not only can chemoattract, but also stimulate proliferation of CD8+ T cells in vitro, and that a mixture of Lptn and IP-10 can more efficiently chemoattract CD8+ T cells than either one of them. Furthermore, we demonstrated that the transferred CD8+ T cells detected in group of tumors treated with both AdVLptn and AdVIP-10 (group a) are around 4 and 2 times more than that in groups of tumors treated with control AdVpLpA (group b) and either AdVIP-10 (group c) or AdVLptn (group d), respectively. Around 87.5% of mice in group a were tumor-free compared to the aggressive tumor growth in all 8 mice of group b and 25% or 37.5% cured mice seen in groups c and d (p<0.05). Thus, our results indicate that enhancement of adoptive T-cell therapy can be obtained by double tranmsgene Lptn and IP-10 expression, which facilitates CD8+ T-cell tumor localization through proliferation and chemoattraction of the transferred CD8+ T cells by in situ chemokine transgene expressions in the tumors. Collectively, our data provide solid evidence of a potent synergy between adoptive T-cell therapy and adenovirus-mediated Lptn and IP-10 gene transfer into tumor tissues, which culminated in the T-cell tumor localization and eradication of well-established tumor masses. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027114     DOI: 10.1002/ijc.20043

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.

Authors:  Yael Langut; Alaa Talhami; Samarasimhareddy Mamidi; Alexei Shir; Maya Zigler; Salim Joubran; Anna Sagalov; Efrat Flashner-Abramson; Nufar Edinger; Shoshana Klein; Alexander Levitzki
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

2.  EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.

Authors:  Alexei Shir; Manfred Ogris; Wolfgang Roedl; Ernst Wagner; Alexander Levitzki
Journal:  Clin Cancer Res       Date:  2010-12-30       Impact factor: 12.531

3.  XCL1 enhances regulatory activities of CD4+ CD25(high) CD127(low/-) T cells in human allergic asthma.

Authors:  Khoa D Nguyen; Alison Fohner; Jerome D Booker; Chen Dong; Alan M Krensky; Kari C Nadeau
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

4.  Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.

Authors:  Africa Wallace; Veena Kapoor; Jing Sun; Paul Mrass; Wolfgang Weninger; Daniel F Heitjan; Carl June; Larry R Kaiser; Leona E Ling; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

5.  EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.

Authors:  Alexei Shir; Manfred Ogris; Ernst Wagner; Alexander Levitzki
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

6.  PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.

Authors:  Yael Langut; Nufar Edinger; Efrat Flashner-Abramson; Naomi Melamed-Book; Mario Lebendiker; Yael Levi-Kalisman; Shoshana Klein; Alexander Levitzki
Journal:  Oncotarget       Date:  2017-04-11

Review 7.  Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.

Authors:  Mei Zhang; Julian A Kim; Alex Yee-Chen Huang
Journal:  Front Immunol       Date:  2018-02-26       Impact factor: 7.561

Review 8.  Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.

Authors:  Christel Devaud; Liza B John; Jennifer A Westwood; Phillip K Darcy; Michael H Kershaw
Journal:  Oncoimmunology       Date:  2013-08-22       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.